Genetic testing for the clinician in prostate cancer. (1st September 2020)

• Record Type: Journal Article
• Authors: López-Campos, Fernando; Linares-Espinós, Estefanía; Maldonado Pijoan, Xavier; Sancho Pardo, Gemma; Morgan, Todd Mathew; Martínez-Ballesteros, Claudio; Martínez-Salamanca, Juan; Couñago, Felipe
• Is Part Of: Expert review of molecular diagnostics. Volume 20:Number 9(2020)
• Page Start: 933
• Page End: 946
• Publication Date: 2020-09-01
• Subjects: Biomarkers -- gene panels -- genetic counseling -- genetic testing -- germline mutation; Molecular diagnosis -- Periodicals; 616.0758205
• DOI: 10.1080/14737159.2020.1816170
• Languages: English
• ISSNs: 1473-7159

Abstract

ABSTRACT: Introduction: Prostate cancer (PCa) is one of the most common cancers worldwide and a leading cause of cancer-related mortality. Although the diagnosis and treatment of prostate cancer has improved substantially in recent years, new molecular biomarkers are needed to further prolong survival and improve the quality of life in these patients. Areas covered: This review analyzes the current evidence for prognostic and predictive molecular biomarkers that can be applied across different clinical scenarios, ranging from localized disease to metastatic castration-resistant PCa, with a particular emphasis on the biomarkers likely to become available in routine clinical practice in the near future. Expert opinion: There is a growing need for molecular testing to identify the most indolent types of prostate cancer to help optimize treatment strategies and spare treatment in these patients when possible. Current trends in the treatment of prostate cancer underscore the unmet clinical need for biomarkers to improve decision-making in a challenging clinical setting.